Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards an understanding of sex differences in functional outcome following moderate to severe traumatic brain injury: a systematic review.

Journal of neurology, neurosurgery, and psychiatry·2008
Same author

Pregabalin in the treatment of spasticity: a retrospective case series.

Disability and rehabilitation·2007
Same author

Mild traumatic brain injury does not predict acute postconcussion syndrome.

Journal of neurology, neurosurgery, and psychiatry·2007
Same author

Combined transcranial direct current stimulation and robot-assisted arm training in subacute stroke patients: a pilot study.

Restorative neurology and neuroscience·2007
Same author

The Papworth Early Rehabilitation Programme: vocational outcomes.

Disability and rehabilitation·2007
Same author

Secondary prevention of arteriosclerosis in lower limb vascular amputees: a missed opportunity.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2006

Related Experiment Video

Updated: May 15, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Spasticity increases during pregabalin withdrawal.

J J Braid1, S G B Kirker, I J Baguley

  • 1Sacred Heart Rehabilitation Unit, St Vincent's Hospital, Sydney, Australia.

Brain Injury
|December 21, 2012
PubMed
Summary

This study found that withdrawing pregabalin (used for spasticity) increased spasticity symptoms. Most patients opted to continue pregabalin therapy due to its effectiveness in managing long-term spasticity.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Spasticity is a common neurological symptom impacting quality of life.
  • Pregabalin is used for spasticity management, but long-term efficacy requires further investigation.

Purpose of the Study:

  • To assess the long-term effectiveness of pregabalin in reducing spasticity.
  • To evaluate patient outcomes following a planned withdrawal of pregabalin.

Main Methods:

  • Prospective service evaluation of 12 patients with spasticity on pregabalin for over 1 year.
  • Graduated pregabalin withdrawal was performed, with pain and spasticity scores assessed.

Main Results:

  • Median spasticity scores significantly increased upon dose reduction (p < 0.01).
  • No significant increase in pain scores was observed.

More Related Videos

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

Related Experiment Videos

Last Updated: May 15, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

  • 91% of participants chose to continue pregabalin therapy post-evaluation.

    • Conclusions:

    • Pregabalin withdrawal leads to increased subjective spasticity without a corresponding rise in pain.
    • Long-term use of pregabalin appears crucial for sustained spasticity management in many patients.